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AbstrAct
background Epilepsy is a common chronic disease 
of children that can be treated with anti-epileptic drugs 
(AEDs). AEDs, however, have significant side effects. Newer 
AEDs are thought to have fewer side effects. There have, 
however, been few comparative studies of AED toxicity. The 
aim is to compare the safety profile of the most frequently 
used AEDs by performing a multicentre prospective cohort 
study. This protocol describes the planned study.
Design A multicentre prospective cohort study of children 
on AED treatment in hospitals across the UK. Ethical 
approval will be obtained.
sample size Three thousand children on treatment 
for epilepsy will be recruited from paediatric clinics. It is 
expected that this sample size will have the potential to 
compare toxicity between the most frequently used AEDs.
Duration of study 24 months.
Outcome measure Adverse drug reactions (ADRs) to 
AEDs. These will be identified by the use of a validated 
questionnaire, the Paediatric Epilepsy Side Effect 
Questionnaire. They will be evaluated using the Naranjo 
algorithm. Preventability will be assessed using the 
Schumock and Thornton scale.
Discussion Toxicity of individual AEDs when given 
as monotherapy and polytherapy will be determined. 
Additionally, discontinuation rates due to ADRs will be 
determined. The data will assist clinicians in choosing 
AEDs with the least toxicity.
IntrODuctIOn
Epilepsy is a widespread disorder affecting 
0.5% children under 16 years old in the 
UK.1 Conventional (old) anti-epileptic drugs 
(AEDs), which are AEDs in use before the 
early 1990s, are still generally preferred to 
the second generation AEDs in children in 
the UK.2 Lamotrigine is the most commonly 
prescribed new generation AED (0.55 
subjects per 1000 person-years).2 A study of 
the UK General Practice Research Database 
showed a fivefold increase in the prevalence 
of newer AED prescription for children in 
2005.3 Over the 13-year period, there was a 
17% decrease in conventional AED prescrip-
tions with a corresponding increase in new 
AED prescriptions.3 This increase in the util-
isation of new AEDs in children presents a 
fresh challenge of identifying new toxicities 
and new drug interactions.
AEDs are the most common cause of 
drug-induced fatalities in children in the UK.4 
A 10-year retrospective review of adverse drug 
reactions (ADRs) in children in the USA also 
identified AEDs as the third most common 
cause of ADRs.5 A report of ADRs in Swedish 
children over a 15-year period (1987–2001) 
showed that lamotrigine was the seventh most 
common cause of ADRs.6 According to a 2012 
UK clinical audit for children with epilepsy, 
lack of sufficient information on side effects 
was identified as one of the most common 
areas for improvement in epilepsy care in 
children.7 Large pharmacovigilance studies 
of ADRs of AEDs in children are lacking. 
Most studies of toxicity of AEDs have focused 
on a single AED.8–10
There have been few prospective cohort 
studies of children with epilepsy on AEDs 
focusing on toxicity.11–13 These studies iden-
tified ADRs in 31%–63% children receiving 
AEDs. The number of children in the studies 
ranged from 102 to 277, which is too small to 
compare the toxicity of the AEDs statistically. 
With the increasing use of new AEDs, there is 
a greater need to determine and compare the 
What is already known on this topic?
 ► Anti-epileptic drugs (AEDs) have significant drug 
toxicity.
 ► New AEDs are being more widely used.
What this study hopes to add?
 ► Comparative data regarding the safety profile of 
individual AEDs.
 ► Discontinuation rates for individual AEDs.
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safety of these drugs, especially with the more established 
old generation drugs.
Randomised controlled trials (RCTs) are useful to 
compare effectiveness of AEDs. They are however, 
rarely, powered to look at toxicity,14 and toxicity is poorly 
described in RCTs.15 Additionally, RCTs of AEDs in chil-
dren are uncommon. Most RCTs of AEDs involve adults 
and children, and the paediatric data are not usually 
reported separately.15 Discontinuation of an AED is due 
to either lack of effectiveness or toxicity. The discontinu-
ation rate to toxicity has ranged from 2% to 30% for most 
AEDs.10 12 16–18
When comparative efficacies are similar, clinicians 
select AEDs based on their safety profile. Studies have 
shown that many of the newer AEDs do not have supe-
rior efficacy to the older drugs, and their relative safety, 
based on the available knowledge, is their only compar-
ative advantage.19 Therefore, large pharmacovigilance 
studies are required to identify ADRs in children and 
adolescents.
Only two validated questionnaires have been devel-
oped for AED ADRs in children. These are the Hague 
Side Effect Scale (HASES)20 and the Paediatric Epilepsy 
Side Effect Questionnaire (PESQ).21 PESQ is the more 
recent of the two, and it was designed to address the 
shortcomings of the HASES that include: validation 
in a small sample size, validation only in patients with 
chronic epilepsy and not being representative of patients 
receiving new generation AEDs. For this study, PESQ will 
be used to elicit ADRs. There have been no prospective 
national multicentre studies of AED toxicity in children. 
Additionally, many of the single-centre studies have not 
used either HASES or PESQ. This study will provide an 
excellent opportunity to use and evaluate the value of 
PESQ in determining the extent of AED toxicity in chil-
dren.
The aim is to perform a prospective cohort study of 
children on AEDs to determine the nature and rate of 
ADRs in this population.
Primary objectives
This study aims to:
 ► describe the incidence of ADRs in children receiving 
each AED
 ► compare the safety profile of the most frequently 
used AEDs
 ► determine discontinuation rates for the most 
frequently used AEDs.
secondary objectives
The secondary objectives are:
 ► to compare toxicity of individual AEDs when given as 
monotherapy and polytherapy
 ► to evaluate the preventability of ADRs in these chil-
dren
 ► to determine the current prescription rates of AEDs 
in children
 ► to describe the effect of factors such as age, dose, 
polypharmacy and duration of treatment on toxicity 
of AEDs.
stuDy DesIgn
study configuration and population
This protocol is for the first multicentre prospective 
cohort study of the safety of AEDs in children in the 
UK. The aim is to prospectively study 3000 children with 
epilepsy for ADRs. We aim to enrol a minimum of 500 
children receiving valproic acid, carbamazepine, lamo-
trigine and levetiracetam, respectively, so as to compare 
the adverse effect profile of these drugs effectively. It is 
expected that this sample size will allow one to compare 
toxicity between the most frequently used AEDs. There 
will be no other intervention other than that obtained 
in routine practice in the respective hospitals. Informa-
tion on ADRs will be extracted and recorded onto a case 
record form.
Paediatric patients receiving AED treatment will 
be recruited from hospital outpatient clinics over a 
period of 12 months. Enrolment shall start as soon as 
the research ethics committee (REC) and research & 
development (R&D) approvals are obtained. The study 
will close at 24 months, after the last recruited patients 
have been followed up for the requisite minimum of 12 
months.
Participants will be recruited from outpatient clinics and 
inpatients attending participating centres (Nottingham 
Children’s Hospital, Derbyshire Children’s Hospital, 
Alder Hey Children’s Hospital Liverpool, Newcastle 
Children’s Hospital, Coventry Hospital and Kings Mill 
Hospital, Mansfield, have all agreed to participate so 
far. It is hoped other centres will also join the study). 
All recruited children will be seen for follow-up in the 
hospitals where treatment was initiated. In order to avoid 
selection bias, all eligible patients will be approached 
for inclusion into the study from general paediatric and 
epilepsy clinics. A member of the potential participant’s 
usual care team will inform the potential participant 
and their parents or guardian about the details of the 
study;this may be directly at their usual clinic visit or by 
a letter from the team about the study, which includes 
the patient information sheet. This information will be 
appropriate for age and maturity of the participants, and 
if required, the usual hospital interpreter and translator 
services will be used. The participant information sheets, 
and consent forms, will only be available in English. 
Patients and their parents/guardian shall be informed 
that participation is voluntary and that they are free to 
withdraw from the study at any time. They shall also be 
informed that refusal to participate or withdrawal from 
the study will not affect the quality of care received. In 
the event of their withdrawal, it will be explained that 
their data collected so far can be withdrawn, and we will 
seek consent to use the data in the final analyses where 
appropriate.
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Inclusion criteria
 ► Paediatric patients with epilepsy aged 18 years or less.
 ► Paediatric patients receiving one or more AEDs for 
epilepsy.
 ► Patients whose parents/guardian have provided 
written informed consent or who have themselves 
(if 16 years old or over) signed a written informed 
consent to participate in the study.
exclusion criteria
 ► Unable or unwilling to give informed consent or with-
drawal of consent.
 ► Plans to relocate to an area not covered by the study.
Study participants will be followed up for 12–18 months.
Data collection
All relevant data will be recorded, by nominated 
member(s) of the research team, on a case report form 
(CRF). Each participant will have a CRF and be assigned 
a unique identification number.
baseline data
At entry into the study, the following baseline informa-
tion will be recorded in the CRF:
 ► unique patient identification number
 ► contact telephone number and/or email address
 ► date of entry into the study
 ► eligibility for study entry based on inclusion/exclu-
sion criteria
 ► age at study entry, in years and months
 ► gender
 ► weight and height
 ► seizure type (eg, generalised tonic clonic, absence, 
myoclonic and partial)
 ► epilepsy syndrome (if identified); epilepsy category
 ► cause of the epilepsy (if identified)
 ► concomitant neurological disorder(s)
 ► the age at diagnosis and duration of epilepsy
 ► seizure frequency recorded as average number of 
seizures per month in the preceding 3 months (for 
patients already on AEDs) or average number of sei-
zures per month since presentation in newly diag-
nosed epileptics
 ► current anticonvulsant(s) with doses and formulation
 ► date of commencement of current AEDs
 ► other medications
 ► concurrent medical disorders
 ► prior or current reported behavioural problems
 ► first recognised seizure date
 ► girls aged 10 years and over will also be asked whether 
they have received advice about contraception and 
possible effects of AEDs on pregnancy.
Follow-up data
Follow-up data will be collected during regularly sched-
uled clinic visits (3–6 monthly). Relevant data will also 
be obtained after any unscheduled clinic visit. This infor-
mation will be obtained from the participants’ hospital 
notes. Important information to be collected at follow-up 
will include:
 ► date of the visit
 ► weight
 ► AEDs, their doses and formulation
 ► plasma concentrations of AEDs (if clinician has re-
quested these and reason for requesting them)
 ► type of seizures since the last visit
 ► emergence of any new seizure types
 ► frequency of seizures, recorded as average number of 
seizures per month since last visit
 ► suspected ADRs since last visit
 ► a detailed record of any change to the drug regime
 ► reason for change in drug regime.
All data on ADRs will be forwarded on to the chief 
investigator.
Outcome evaluation
The main outcomes are ADRs. The methods used to 
detect the ADRs and their evaluation and classification 
are described below.
ADr surveillance
Surveillance for ADRs will be carried out prospectively 
on all patients in the cohort by the clinician, researcher, 
parents/guardian and the patient. Patients will be 
followed up 3–6 monthly for 12–18 months. If a patient 
experiences an ADR to one AED that results in a change 
in therapy, then the monitoring will continue for up to a 
maximum of 18 months.
ADRs will be detected by administering a validated ques-
tionnaire for ADRs (PESQ) to patients or their parents.22 
Only ADRs occurring within the preceding 3 months of 
enrolment will be recorded. During each of the follow-up 
visits, attending physicians will also ask parents/patients 
generally about the occurrence of any adverse reaction. 
ADR information from this general enquiry will be docu-
mented on a specifically designed form that will be kept 
in the patient’s case notes. Patients will have a total of at 
least three follow-up visits. The follow-up visits will ensure 
that transient self-correcting ADRs are distinguished 
from more clinically significant ADRs.
At enrolment, participants will be asked if they wish to 
be contacted by email or by telephone. For participants 
who wish to be contacted by email, a 3 monthly email will 
be sent to parents/guardian or directly to the participant 
(if 16 years old or more). This will be sent by a nominated 
member of the research team. The email will include 
a link to the PESQ, which the patients/parents will be 
required to fill anonymously (table 1). For participants or 
their parents/guardian who wish to be contacted by tele-
phone, they will be contacted and questions regarding 
ADRs from the structured questionnaire (PESQ) will be 
asked. The attending physicians will be notified of any 
severe ADR indicated by the patients or parents on the 
PESQ.
Information from general ADR enquiry will be docu-
mented on a follow-up visit form by the attending 
 o
n
 22 M
ay 2018 by guest. Protected by copyright.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2017-000116 on 4 August 2017. Downloaded from 
4 Egunsola O, et al. BMJ Paediatrics Open 2017;1:e000116. doi:10.1136/bmjpo-2017-000116
Open Access
Table 1 The Paediatric Epilepsy Side Effect Questionnaire (PESQ)
Side effect related to 
seizure medicine
Not present
(1)
Low 
severity (2)
Low–-
moderate 
severity(3)
Moderate 
severity
(4)
Moderate–-
high 
severity(5)
High severity
(6)
1 Slow thinking
2 Memory problems
3 Confusion
4 Poor school results
5 Decreased 
concentration
6 Attention difficulties
7 Unstable walking
8 Poor coordination, 
clumsiness
9 Falling (not seizure)
10 Speech difficulties
11 Aggression
12 Hyperactivity
13 Personality change
14 Drowsiness, sleepiness
15 Fatigue, tiredness
16 Dizziness, 
lightheadedness
17 Headaches
18 Increase in appetite
19 Weight gain
20 Others
physician during each follow-up visit. This will supple-
ment all ADR information elicited specifically with the 
questionnaire. The clinical course of each suspected 
ADR will be followed until resolution or stabilisation. All 
prescription changes, interventions, laboratory findings 
and the time course relationship of the reaction to the 
medication will be documented. The progress of the ADR 
will be monitored in subsequent clinic visits to determine 
if it is unchanged, has resolved or worsened.
If AEDs are changed, a member of the research team 
will determine from the participant’s notes the reason 
for the prescription change. If the reason for the change 
is not satisfactorily stated in the notes, a member of the 
research team may enquire from the attending physi-
cian. In the event of a child experiencing an ADR, any 
relevant clinical blood tests will be performed if deemed 
necessary by the treating clinician, and this may include 
determination of a drug level where applicable. In the 
event of a child experiencing an ADR, any relevant clin-
ical blood tests will be performed if deemed necessary by 
the treating clinician, and this will include determination 
of a drug level where applicable. The attending physician 
shall take all necessary steps to mitigate the ADR. This 
may include: discontinuation of the drug or any other 
concomitant drug or reduction in drug dosages. The 
participants and their parents/guardians will be fully 
informed of all the measures towards ameliorating the 
effect of the ADR.
evaluation and classification of suspected ADrs
All suspected ADRs will be assessed by a member of the 
research team, by using the Naranjo algorithm, which 
is a standardised causality assessment tool for suspected 
ADRs.9 This method has previously been used in paedi-
atric ADR surveillance studies.11 12
All suspected ADRs will be evaluated and classified13 as:
Definite
A clinical event or abnormal laboratory test finding that 
has a plausible time relationship to the drug and cannot 
be explained by disease or concomitant drug. There is 
usually a favourable response to drug withdrawal and 
recurrence on rechallenge. This ADR will have a Naranjo 
score of 9 or more.
Probable
A clinical event or abnormal laboratory test with a reason-
able time course relationship to the administered drug 
and not due to other drugs or concurrent disease. There 
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is a reasonable favourable response on withdrawal. This 
will have a Naranjo score of 5–8.
Possible
A clinical event or abnormal laboratory finding with a 
reasonable time course relationship to the drug but could 
also be explained by a concomitant drug or a concurrent 
illness. This will have a Naranjo score of 1–4.
Not related
No possible relationship (ie, the temporal relationship 
between treatment exposure and the adverse event 
onset/course is unreasonable or incompatible; or a 
causal relationship to study treatment is implausible). 
This will have a Naranjo score of <1.
ADRs considered to be unrelated to treatment will 
not be included in the analysis of incidence rates and 
will not be included when comparing toxicity. All other 
ADRs (definite, probable and possible) will be combined 
together when comparing toxicity.
The severity of ADRs will be classified in accordance 
with previously used method22 23
1. Severe: fatal or potentially life threatening.
2. Moderate: requiring treatment or prolonging the 
length of stay in hospital.
3. Mild: no treatment required and no effect on length 
of stay in hospital.
Severe ADRs will be reported to the Committee on 
Safety of Medicines.
calculation of incidence of ADrs and discontinuation rates
The most valuable comparative data will be from patients 
who are receiving monotherapy. The incidence rate 
for specific ADRs in relation to a specific AED will be 
calculated by dividing the number of cases of the ADR 
occurring while on treatment with the number of chil-
dren receiving the AED. The duration of treatment with 
the AED will be used to calculate the incidence of the 
ADR in relation to time. An incidence rate per child 
per year will be calculated. Discontinuation rates will be 
calculated by dividing the number of children who termi-
nated treatment with an AED due to toxicity, divided by 
the number of children who received the drug.
Preventability of ADrs
The preventability of ADRs will be assessed using the 
Schumock and Thornton scale.24 This scale, which has 
been used previously in another AED pharmacovigilance 
study,12 evaluates the preventability of ADRs based on a set 
of seven questions. These questions cover the appropri-
ateness of the medicine; the dose, route and frequency of 
administration; therapeutic drug monitoring and serum 
concentrations (if appropriate); allergy; drug interac-
tions and adherence.
statistics
The primary outcome will be the incidence of ADRs 
for each of the prescribed AED. Using χ2 analysis, and 
Fischer’s exact test when appropriate, ADRs and discon-
tinuation rates of individual AEDs will be compared.
Secondary outcomes will be the effects of polytherapy 
and monotherapy on ADRs and discontinuation rates. χ2 
analysis, and Fischer’s exact test when appropriate, will 
be used. Other secondary outcomes such as the associ-
ation between age and type of epilepsy with ADR will be 
analysed using one-way analysis of variance. Multivariate 
logistic regression will be used to determine the predic-
tors of ADRs in children receiving AEDs. Excel and SPSS 
will be used for statistical analyses.
ethics and dissemination
The study will only be initiated after the protocol, consent 
form and the participants’ information sheet are approved 
by the REC, and the respective National Health Service 
(NHS) R&D departments. If an amendment to the 
protocol requiring REC approval is necessary, such amend-
ments will not be effected until revised informed consent 
forms and participant information sheets are reviewed and 
approved by the R&D departments and the REC. Should 
the amendment be intended to prevent a clear immediate 
hazard to participants, such amendment may be effected, 
provided that the REC are notified as soon as possible and 
an approval is requested. Minor protocol amendments 
only for logistical or administrative changes may be imple-
mented immediately, and the REC will be informed.
The study will be conducted in compliance with the 
principles of: Good Clinical Practice, the Department 
of Health Research Governance Framework for Health 
and Social Care, 2005, and in accordance with the 1996 
Declaration of Helsinki.
Informed consent
Written informed consent will be obtained from parents/
guardian of potential participants less than 16 years old, 
at the time of clinic appointment. Written consent will 
be sought directly from patients 16 years old or over. 
If a participant turns 16 years old during the course of 
the study, consent will be sought from the participant in 
order to continue participation in the study. The inves-
tigator will explain the details of the study and provide 
age-appropriate participant information sheet to the 
participants and their parents/guardian. All questions 
about the study, by either the patient and or the parent/
guardian, will be answered by the investigator. Partici-
pants will be allowed sufficient time to decide whether 
to participate in the study or not. Before enrolment into 
the study, the consent form will be signed by parents/
guardian, or by the participant if aged 16 years or more. If 
either the potential participant or their parent/guardian 
decline to consent, or if under 16 years of age the child 
or young person declines to be included, they will not 
enter the study.
The participant or their parent/guardian will keep a 
copy of the consent form, while the original copy will be 
kept by the chief investigator in the recruitment file, a 
third copy will be kept in the patient’s hospital record. In 
the event of a significant protocol change, a fresh signed 
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written consent will be sought from participants, parents 
or guardians, and the revised document will be submitted 
to the REC and the sites’ R&D for approval. Assent will be 
sought from any patient considered mature enough to 
comprehend the importance of the study.
Discontinuation of study participation
Participants may choose to withdraw from the study, on 
their own or on the request of their parents/guardian, 
at any time during the course of the study. Subjects may 
withdraw for any reason without prejudice to his/her 
future medical care by the physician or at the institu-
tion. On withdrawal of consent, the date and reason for 
consent withdrawal will be documented. Participants’ data 
collected up to the date of the withdrawal of consent may 
be included in the final analysis. The investigator may also 
choose to withdraw a participant from the study if such 
person is lost to follow-up, has moved out of the study area, 
does not comply with treatment or for any other practical 
reason that may affect the integrity of the study. Withdrawn 
participants will not be replaced.
study records and data management
Case report forms
Each participant will be assigned a unique study patient 
identification number, for use on CRFs, other study docu-
ments and the electronic database. CRFs will be treated as 
confidential documents and held securely in accordance 
with regulations. The investigator will make a separate 
confidential record of the participant’s name, date of 
birth, local hospital number or NHS number and patient 
identification number to permit identification of all partic-
ipants enrolled in the study, in case additional follow-up is 
required.
CRFs shall be restricted to those personnel approved by 
the chief investigator and recorded as such in the study 
records.
All paper forms shall be filled in using black ballpoint 
pen. Errors shall be lined out but not obliterated by using 
correction fluid and the correction inserted, initialled 
and dated.
The chief investigator shall sign a declaration ensuring 
accuracy of data recorded in the CRF.
record retention and archiving
The chief investigator will retain all records and docu-
ments pertaining to the study for 7 years in compliance 
with the International Conference on Harmonisation/
Good Clinical Practice guidelines and the University of 
Nottingham Code of Research Conduct and Research 
Ethics. If the responsible investigator can no longer retain 
these records, another person will be nominated for this 
purpose.
The final archiving of the study documents and data-
bases (and associated meta-encryption codes) held by the 
chief investigator shall be at the secure archive facility at 
the University of Nottingham.
Publication and dissemination policy
Participants will not be paid to participate in the study. 
There will be no hospital visits in excess of usual care. Find-
ings will be published in peer-reviewed journals.
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